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 2 
ABSTRACT 24 
Despite the availability of two attenuated vaccines, rotavirus (RV) gastroenteritis 25 
remains an important cause of mortality among children in developing countries causing 26 
about 215,000 infant deaths annually. Currently, there are no specific antiviral therapies 27 
available. RV is a non-enveloped virus with a segmented double-stranded RNA genome. Viral 28 
genome replication and assembly of transcriptionally active double-layered particles (DLPs) 29 
take place in cytoplasmic viral structures called viroplasms. In this study, we describe strong 30 
impairment of the early stages of RV replication induced by a small molecule known as RNA 31 
polymerase III inhibitor, ML-60218 (ML). This compound was found to disrupt already 32 
assembled viroplasms and hamper the formation of new ones without the need of de 33 
novo transcription of cellular RNAs. This phenotype correlated with reduction in accumulated 34 
viral proteins and newly made viral genome segments, disappearance of the 35 
hyperphosphorylated isoforms of the viroplasm-resident protein NSP5 and inhibition of 36 
infectious progeny virus production. In in vitro transcription assays with purified DLPs, ML 37 
showed a dose-dependent inhibitory activity indicating the viral nature of its target. ML was 38 
found to interfere with the formation of higher order structures of VP6, the protein forming the 39 
DLP outer layer, without compromising its ability to trimerize. Electron microscopy of ML-40 
treated DLPs showed a dose-dependent structural damage. Our data suggest that 41 
interactions between VP6 trimers are essential not only for DLP stability but also for the 42 
structural integrity of viroplasms in infected cells. 43 
 44 
IMPORTANCE 45 
Rotavirus gastroenteritis is responsible for a large number of infant deaths in 46 
developing countries. Unfortunately, in those countries where effective vaccines are urgently 47 
 o
n
 January 29, 2020 at G
lasgow University Library
http://jvi.asm.org/
D
ow
nloaded from
 
 3 
needed, the efficacy of the available vaccines is particularly low. Therefore, the development 48 
of antivirals is an important goal, as they might complement the available vaccines or 49 
represent an alternative option. Moreover, they may be decisive in fighting the acute phase of 50 
infection. This work describes the inhibitory effect on rotavirus replication of a small molecule 51 
initially reported as an RNA polymerase III inhibitor. The molecule is the first chemical 52 
compound identified able to disrupt viroplasms, the viral replication machinery, and to 53 
compromise the stability of DLPs by targeting the viral protein VP6. This molecule thus 54 
represents a starting point towards the development of more potent and less cytotoxic 55 
compounds against rotavirus infection. 56 
 57 
INTRODUCTION 58 
Rotavirus (RV) is the most common cause of gastroenteritis in young children and 59 
infants throughout the world. The impact of RV vaccines on global estimates of RV mortality 60 
has been limited, and the rate of deaths due to RV gastroenteritis in developing countries is 61 
still approximately between 197,000–233,000 per year (1). Currently, there are no specific 62 
antivirals available. The virus belongs to the Reoviridae family, is non-enveloped and contains 63 
a genome of eleven segments of double-stranded RNA. During entry into the host cell 64 
(enterocytes of the intestinal villi), the virion (triple-layered particle, TLP) loses the outer of its 65 
three concentric protein layers formed by the glycoprotein VP7 and the spike protein VP4 and 66 
becomes a transcriptionally active double-layered particle (DLP). The viral RNA-dependent 67 
RNA polymerase VP1 acts both as transcriptase (synthesis of viral mRNAs) and as replicase 68 
(synthesis of minus strands resulting in new genome segments) (2). To be transcriptionally 69 
active, VP1 must be localized within a DLP. Both DLP layers, the inner one formed by VP2 70 
and the outer one formed by VP6 trimers, are required to guarantee transcriptional activity. 71 
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 4 
Removal of VP6 from DLPs abolishes this activity, which can be recovered by adding native 72 
or recombinant VP6 (3, 4). The transcribed plus-stranded RNAs act as both messengers for 73 
viral protein synthesis and templates for viral genome replication. The viral genome is 74 
replicated in viral cytoplasmic structures called viroplasms, where also the assembly of 75 
progeny DLPs takes place. These newly synthesized DLPs perform a second round of 76 
transcription, called secondary transcription, which produces additional plus-stranded RNAs 77 
(5, 6). In the final stages of virus morphogenesis, the progeny DLPs bud into the ER acquiring 78 
a transient envelope, which is then replaced by the viral proteins (VP7, VP4) forming the outer 79 
layer of progeny TLPs (2). 80 
In addition to the structural proteins forming DLPs (VP1, the capping enzyme VP3, 81 
VP2, and VP6), two viral non-structural proteins are also found in viroplasms: NSP5 and 82 
NSP2. Both are essential for viroplasm formation and therefore for viral replication (6-9). 83 
During viral infection, NSP5 undergoes a complex hyperphosphorylation process involving 84 
different kinases and interactions with other viral proteins (10-12). However, the role of this 85 
post-translational modification in the viral replication cycle is not completely understood. In 86 
fact, several lines of evidence show correlation between viroplasm formation and NSP5 87 
phosphorylation (13-15). Also, NSP2 and VP2 were recently found phosphorylated, and it has 88 
been proposed that viroplasm formation is a phosphorylation-dependent process (11). 89 
 The number and size of viroplasms in infected cells are indicative of viral replication 90 
efficiency. These values decrease in the presence of compounds with antiviral effect on the 91 
early steps of the viral cycle, like inhibitors of proteasome (16), microtubules (MT) (17), Eg5 92 
kinesin (17) and thiazolides (18), that interfere with viroplasm assembly and virus infectivity. 93 
Ribavirin has also been reported to affect RV replication (19). In this work, we describe the 94 
unexpected antiviral activity of a chemical compound, ML-60218 (referred to as ML), reported 95 
 o
n
 January 29, 2020 at G
lasgow University Library
http://jvi.asm.org/
D
ow
nloaded from
 
 5 
as an inhibitor of the RNA polymerase III complex (20). The effect on RV shown here is 96 
independent of the RNA polymerase III catalytic activity. For the first time, we describe a 97 
chemical compound able to disrupt viroplasms in virus-infected cells and compromise the 98 
stability of purified DLPs by interfering with interactions between VP6 trimers. 99 
 100 
RESULTS 101 
ML impairs viroplasm formation and disrupts already assembled viroplasms. Treatment 102 
of RV-infected cells with ML at 10 μM caused a strong reduction of viroplasms accumulated 103 
during viral replication and, in the case of the porcine OSU strain, a complete disappearance 104 
of those structures, as observed by both immunofluorescence (Fig. 1) and electron 105 
microscopy analysis (Fig. 2). Independently of whether the compound was added at 1, 3 or 5 106 
hours post-infection (hpi), a 4 h treatment had the same effect on viroplasms (Fig. 1A). 107 
Viroplasm disruption correlated with a decrease of accumulated viral proteins, as observed 108 
with the porcine OSU and the simian SA11 strains (Fig. 1B). When added before infection, 109 
together with the infectious virion, or at 1 hpi (Fig. 1C, upper panel), ML caused a reduction of 110 
viral proteins in a dose-dependent manner with a concomitant disappearance of the NSP5 111 
hyperphosphorylated isoforms (Fig. 1C, middle panel). ML added at the concentration of 10 112 
μM together with the infectious virions completely blocked assembly of viroplasms (Fig. 1C, 113 
bottom panel). The same phenotype was observed in two different cell lines (monkey kidney 114 
epithelial MA104 cells and human osteosarcoma U2OS cells) upon infection with two different 115 
RV strains (OSU and SA11) (Fig. 1D and E). 116 
The absence of viroplasms and the reduction of accumulated viral proteins indicate 117 
that ML inhibits RV replication. This result was confirmed assessing the yield of infectious 118 
progeny virus produced at different time points post-infection (Fig. 1F) and the production of 119 
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 6 
newly made dsRNA genome segments (gs) (Fig. 1G). During the time intervals of the 120 
analysis, ML was not cytotoxic (Fig. 1H). 121 
Three hours was the minimum time and 10 μM the minimal concentration required for 122 
complete effect on viroplasms (data not shown). Concentrations higher than 20 μM were toxic 123 
for cells, as shown by the decreased levels of actin in Western blots (Fig. 1C). Treatments of 124 
up to 12-14 h at 10 μM were well tolerated (Fig. 1H). 125 
ML-mediated viroplasm disruption causes NSP5 dephosphorylation. In order to 126 
determine whether the effect of ML on NSP5 phosphorylation was due to activation of 127 
phosphatases, 0.5 μM okadaic acid (an inhibitor of serine/threonine phosphatases) was 128 
added to OSU-infected cells at 3 hpi (1 h before the addition of ML), and maintained during 129 
the following 4 h treatment (see scheme in Fig. 3). Upon inhibition of phosphatases with 130 
okadaic acid, the effect of ML on viroplasms remained unaltered (Fig. 3, bottom right panel) 131 
but NSP5 hyperphosphorylated isoforms did not disappear (Fig. 3, lane 2). This result 132 
suggests that the effect of ML on viroplasms is not mediated by activation of phosphatases 133 
and that NSP5 dephosphorylation is the consequence of disruption of viroplasms which, when 134 
intact, protect NSP5 from cytosolic phosphatases. 135 
ML activity against RV does not require newly synthesized cellular transcripts or 136 
proteins and is independent of the RNA polymerase III catalytic activity. To determine 137 
whether the phenotype observed under ML treatment was due to de novo synthesis of cellular 138 
proteins or RNAs, actinomycin D was added to cells at 3 h post-infection, one hour before 139 
treatment with the drug, and maintained during the following 4 h treatment (see scheme in 140 
Fig. 4A). Actinomycin D is a DNA intercalator that inhibits transcription of RNA polymerase I 141 
at very low concentrations (>0.01 μg/ml), of RNA polymerase II at concentrations higher than 142 
2 μg/ml, and of RNA polymerase III at concentrations higher than 5 μg/ml (21, 22). Newly 143 
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 7 
synthesized RNAs were labeled with the ribonucleoside homolog 5-ethynyl uridine (EU) and 144 
visualized by reacting with an Alexa-488 conjugated azide (green) (Fig. 4A, right panel) to 145 
assess the effectiveness of actinomycin D treatment. Actinomycin D at 10 μg/ml did not 146 
interfere with the effect of ML indicating that newly synthesized cellular transcripts are not 147 
required for ML antiviral activity. Also, in the absence of ML, treatment with actinomycin D did 148 
not compromise viroplasm integrity nor affected the accumulation of viral proteins (Fig. 4A, 149 
left panel). On the contrary, it slightly increased the amounts of VP2 and NSP5 compared to 150 
the untreated control (Fig. 4A, lane 2 vs. lane 1). This result explains why actinomycin D was 151 
found to compensate the decrease of VP2 induced by ML (Fig. 4A, left panel, lane 4 vs. lane 152 
3). All these data indicate that RV replication does not require the catalytic activity of RNA 153 
polymerase III and that ML activity against RV is not mediated by inhibition of this cellular 154 
target. In addition, de novo protein synthesis is not required for ML activity. Addition of ML (at 155 
4 hpi) to cells treated with the protein synthesis inhibitor cycloheximide (CHX) (added at 3 hpi) 156 
still caused viroplasm disruption and NSP5 dephosphorylation (Fig. 4B). 157 
ML compromises DLPs stability. We then investigated whether ML acts on a viral target. 158 
RV DLPs were purified from cells infected with OSU or SA11 strains, and their transcriptional 159 
activity tested in vitro in the presence of increasing ML concentrations. An irrelevant small 160 
molecule (compound #7749832, ChemBridge Corp.) solubilized in the same buffer was used 161 
as a control. Upon incubation with ML, the number of transcripts produced by DLPs of both 162 
strains was significantly decreased in a dose-dependent manner (Fig. 5A) as compared to the 163 
vehicle or the irrelevant small molecule. An IC50 of 10 μM was observed for both viruses. In 164 
order to be transcriptionally active, DLPs must be intact. The sole absence of the external 165 
layer formed by VP6 trimers is sufficient to compromise the transcriptional activity (3, 4, 21). 166 
Interestingly, electron microscopy (EM) analyses on purified DLPs showed that 4 h incubation 167 
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 8 
with ML (in the same buffer used for the in vitro transcription assays) caused structural 168 
damage in a dose-dependent manner. DLPs with an irregular shape and partially open were 169 
observed (Fig. 5B). Quantifications in all samples are plotted in Fig. 5C. Altogether these 170 
results suggest that ML compromises the structural integrity of DLPs, thus impairing their 171 
transcriptional activity. 172 
ML interferes with higher order VP6 structures. Although ML clearly altered DLP 173 
morphology, the EM images showed the presence of residual structures (Fig. 5, white 174 
arrows). These structures could be DLPs partially or totally deprived of the VP6 layer.  175 
We thus investigated whether ML impaired the interaction of VP6 with VP2 or with itself, as in 176 
the formation of trimers or in the interactions between trimers. 177 
The VP6-VP2 interaction was tested by co-immunoprecipitation with an anti-VP6 178 
monoclonal antibody (clone RV-138) from cells overexpressing both VP6 and VP2 and 179 
treated for 5 h with ML. The inhibitor was also maintained during cell lysis and incubation with 180 
the precipitating antibody. The experiment, repeated at various ML concentrations (up to the 181 
highest concentration used of 200 μM), showed that ML did not interfere with VP6-VP2 182 
interactions (Fig. 6A). 183 
VP6 trimer formation was assessed by Western blots of non-boiled lysates from cells 184 
overexpressing VP6 and treated with ML. In fact, VP6 trimers (MW = 135 kDa) resist SDS 185 
denaturing and reducing conditions but not high temperatures (23). Cells infected with a 186 
recombinant vaccinia virus expressing VP6 (vvVP6) were treated with ML at 1 hpi for 7 h. 187 
VP6 trimers formed in vivo were not affected by the presence of ML (Fig. 6B, left panel), 188 
which did not compromise the total levels of VP6 expression. Intact VP6 trimers were also 189 
found in RV-infected cells treated with ML, although in decreased amounts because of the 190 
reduced viral replication (Fig. 6B, right panel). ML, however, appears to interfere with the 191 
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 9 
formation of VP6 higher order structures typically observed in cells overexpressing VP6 in the 192 
absence of other RV proteins (24) (Fig. 6C). In immunofluorescence, VP6 staining showed 193 
tubular structures or aggregates, while in the presence of ML it showed homogenous 194 
distribution (Fig. 6C). In contrast, other structures such as viroplasm-like structures (VLS) 195 
generated by overexpression of NSP5 with NSP2 (VLS-NSP2i) or with VP2 (VLS-VP2i) (24, 196 
25) or with both, were not affected by ML treatment (Fig. 7A, C). Under these conditions, 197 
NSP5 remained hyperphosphorylated and VP6 recruitment into VLS was not compromised 198 
(Fig. 7B-C). 199 
Depending on pH and ionic strength, purified VP6 self-assembles into helical tubes or 200 
spherical particles ((26) and Fig. 6D, left panels). Two different types of tubes can be 201 
reconstituted in vitro, characterized by a constant diameter of either 45 or 75 nm with a non-202 
fixed length of several μm. On the other hand, VP6 spheres are heterogeneous in size with 203 
diameters varying from 75 to 100 nm (26, 27). In order to evaluate whether ML had an effect 204 
on the assembly of these VP6 structures, we performed a negative staining electron 205 
microscopy analysis on purified VP6 in the presence or absence of ML. Upon incubation with 206 
25 µM ML, both VP6 tubes (pH 6.0) and spherical particles (pH 4.0) were severely damaged 207 
(Fig. 6D). In fact, a thorough visual inspection of the EM grids failed to reveal any intact tube 208 
or sphere in the presence of ML (Fig. 6D, right panels). Thus, ML has a direct effect on the 209 
higher order interactions of VP6 trimers. 210 
To further study the effect of ML on VP6, the interaction between the protein and the 211 
drug was evaluated in nanoscale thermophoresis assays. Upon addition of the inhibitor, a 212 
concentration-dependent quenching of the labeled protein was observed, which allowed us to 213 
calculate an EC50 value of 294  62 µM (Fig. 6E). Since millimolar concentrations of divalent 214 
cations are known to destabilize the VP6 higher order structures shifting the equilibrium 215 
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 10 
toward isolated trimers (26), thermophoresis mobility was also tested in the presence of CaCl2 216 
(up to 500 mM). No significant changes were observed (data not shown). Thus, in the 217 
thermophoresis experimental conditions, the signal observed was due to direct binding of ML 218 
to VP6 trimers, rather than to a destabilization of its oligomerization state. Altogether, these 219 
results suggest that, although ML binds VP6 trimers with moderate affinity, it likely prevents 220 
the optimal packing of its higher oligomeric structures on the DLP outer layer. Whether this is 221 
due to a conformational change induced by the molecule or to a steric hindrance effect is not 222 
known and awaits structural confirmation. 223 
The effect of ML on viroplasms and VP6 strongly indicates that VP6 plays an essential 224 
role in the structural integrity of viroplasms. In fact, as already reported (5), silencing VP6 225 
expression with a specific siRNA led to a significant reduction of viroplasm number in RV-226 
infected cells (Fig. 8A), strengthening the hypothesis that VP6 is essential for maintaining the 227 
structure of viroplasms. Of note, in ML-treated virus-infected cells VP6 was found diffused 228 
throughout the cytosol (Fig. 8B). 229 
 230 
DISCUSSION 231 
We describe for the first time a compound able to disrupt already formed RV 232 
viroplasms in infected cells, thus impairing RV replication as demonstrated by the decrease in 233 
viral protein translation, de novo synthesis of viral genomic dsRNA and yield of progeny virus. 234 
This effect of ML on RV replication was initially surprising because this drug, a cell-235 
permeating indazole-sulfonamide small molecule, has been described to favor replication of 236 
some DNA viruses and bacteria by inhibiting the RNA polymerase III-mediated mechanism 237 
that activates the RIG-I pathway (28-30). RV, however, is an RNA virus. We ruled out that ML 238 
inhibition was mediated by RNA polymerase III activity as actinomycin D, used at a 239 
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 11 
concentration that inhibits RNA polymerase III transcription, still allowed RV replication. In 240 
addition, actinomycin D was unable to counteract the ML antiviral effect, indicating that ML 241 
antiviral activity does not require synthesis of newly made cellular transcripts, including those 242 
of RNA polymerase III. This is consistent with the finding that the ML target is of viral nature. 243 
We showed that ML impaired DLP stability in vitro by inhibiting the interactions between VP6 244 
trimers. In the absence of a correctly assembled VP6 layer, DLPs lose the capacity to 245 
transcribe plus-stranded RNAs (3, 31). These results explain the decreased amount of 246 
transcripts obtained in vitro from purified DLPs and provide the basis for the reduced amounts 247 
of viral proteins and dsRNAs observed in infected cells treated with ML. Altogether these data 248 
indicate that the inhibitor binds VP6, compromising both the integrity of DLPs and the 249 
structure of viroplasms.  250 
The mechanism of viroplasm assembly is still not well understood. Viroplasms contain 251 
six viral proteins: two non-structural, NSP5 and NSP2 (both shown to be essentially required 252 
for viroplasm formation (6, 7, 32)), and four structural proteins, VP1, VP2, VP3 and VP6 (33). 253 
Electron microscopy studies suggested that newly made DLPs assemble at the periphery of 254 
viroplasms (34). Immunogold labeling of VP6 indicated that this protein localizes exclusively 255 
at the periphery of viroplasms, while NSP5, NSP2, and VP2 were also detected in the 256 
viroplasm interior (Arnoldi et al., unpublished results). Silencing VP6 expression leads to 257 
fewer and smaller viroplasms and reduced amounts of viral mRNAs, viral dsRNAs and viral 258 
proteins (5), indicating that this protein is also required for the structural and functional 259 
integrity of viroplasms. We confirmed that knocking down VP6 expression produced a sharp 260 
reduction in the number of viroplasms (Fig. 8 and (5)), consistently with the capacity of ML to 261 
hamper viroplasms by interaction with VP6. However, it is not clear whether the destabilizing 262 
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 12 
effect on viroplasm structure is the consequence of damaging the VP6 layer in newly 263 
assembled DLPs or impairing VP6 interactions outside the context of DLPs. 264 
Disruption of already assembled viroplasms was particularly evident with OSU and less 265 
pronounced with SA11, suggesting that viroplasms may have different stability depending on 266 
the strain. The decrease of accumulated viral proteins was nevertheless comparable with the 267 
two strains and suggests that ML targets a structural region of VP6 that is conserved among 268 
different viruses. 269 
Noteworthy, ML did not interfere with formation of VLS nor with recruitment of VP6 into 270 
VLS, suggesting that: i) ML does not target the interactions required for VLS assembly (NSP5 271 
with either NSP2 or VP2) or for recruitment of VP6 into VLS, that depends on its interaction 272 
with VP2 (24); ii) VLS are clearly different from viroplasms, as previously reported (16). The 273 
lack of ML effect on VP2-VP6 interaction was further confirmed by the co-immunoprecipitation 274 
experiments. 275 
Interestingly, a strong reduction of NSP5 hyperphosphorylation was observed upon 276 
treatment with ML. NSP5 hyperphosphorylation has been associated to RV replication 277 
because of its link with viroplasm formation: i) the two events have been found correlated 278 
during the course of viral infection (15); ii) overexpression of NSP5 with either NSP2 or VP2 in 279 
uninfected cells induces both NSP5 hyperphosphorylation and VLS formation (13, 24, 25, 35); 280 
iii) silencing of casein kinase 1-alpha that affects NSP5 phosphorylation (but does not abolish 281 
it entirely) produces viroplasms with irregular shapes (14). Recently, it was shown that at the 282 
beginning of infection hypophosphorylated NSP5 interacts with a cytoplasmically dispersed 283 
form of NSP2 and was then proposed that during infection phosphorylation of not only NSP5, 284 
but also of NSP2, and possibly of VP2, leads to viroplasm maturation (11). Our data in cells 285 
treated with both ML and the phosphatase inhibitor okadaic acid show for the first time that 286 
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NSP5 can remain hyperphosphorylated in infected cells in the absence of viroplasms. Such 287 
finding indicates that viroplasms protect NSP5 from dephosphorylation. This result in part 288 
supports the model suggested by Criglar et al. (11) that proposes an initial interaction among 289 
non- or hypophosphorylated viral proteins. However, although a mechanism of concerted 290 
phosphorylation involving several proteins of viroplasms might be necessary for subsequent 291 
viroplasm maturation and functioning, our data suggest that NSP5 hyperphosphorylation is 292 
necessary but not sufficient for viroplasm formation. In this regard, treatment of uninfected 293 
cells expressing recombinant NSP5 with inhibitors of cellular phosphatases leads to NSP5 294 
hyperphosphorylation, but not to VLS formation (36).  295 
So far, a few types of molecules such as proteasome inhibitors (MG132, Bortezomib) 296 
(16), MT-depolymerizing drugs (nocodazole, vinblastine) (17), an allosteric inhibitor of Eg5 297 
kinesin (monastrol) (17) and thiazolides (18) were shown to affect RV viroplasms. 298 
Proteasome inhibitors impair the formation of new viroplasms without affecting the stability of 299 
those already assembled, do not show any inhibitory activity on RV particles in vitro and do 300 
not interfere with the formation of VLS in transfected cells. Although the inhibition mechanism 301 
remains obscure, it was hypothesized that the effect was the consequence of blocking 302 
proteasome-mediated degradation of an unknown host factor capable of impairing formation 303 
of viroplasms (16, 37). Regarding MT-depolymerizing drugs and Eg5 kinesin inhibitor, they 304 
both destabilize the viroplasm structure and their coalescence but do not reduce viral proteins 305 
expression (17). Finally, treatment with thiazolides causes a reduction in the viroplasm size, 306 
resulting in an inhibition of the dsRNA genome segments synthesis, but without impairing viral 307 
protein expression or affecting stability of RV particles (18). Importantly, the compound 308 
described in this work is the only RV inhibitor so far identified that can disrupt viroplasms and 309 
acts on a viral target. This makes the chemical structure of ML particularly appealing for 310 
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further studies in the field of antivirals. As such, ML could not be used as an antiviral drug, 311 
because of its cytotoxicity. However, future research and structural analyses might lead to the 312 
development of more potent and selective inhibitors as potential drugs against RV infections. 313 
 314 
MATERIALS AND METHODS 315 
Cells and viruses. MA104 cells (embryonic African green monkey kidney cells, ATCC® CRL-316 
2378) were grown in Dulbecco's Modified Eagle's Medium (DMEM) (Life Technologies) 317 
containing 10% Fetal Bovine Serum (Life Technologies), and 50 μg/ml gentamycin (Biochrom 318 
AG). BSC-40 cells (green monkey kidney epithelial cells, ATCC® CRL-2761) were cultured in 319 
DMEM supplemented with 10% fetal calf serum (AMIMED, Switzerland) and penicillin (100 320 
units/ml)-streptomycin (0.1 mg/ml) (Sigma). Sf9 cells (Spodoptera frugiperda ovary cells, 321 
ATCC® CRL-1711™) were grown in suspension in Sf-900™ II SFM medium (Thermo Fisher 322 
Scientific) at 27°C. 323 
For RV-infection experiments, the porcine OSU (G5, P9[7]) and simian SA11 4F (G3, 324 
P6[1]) strains of RV were used; they were propagated in MA104 cells as described previously 325 
(38, 39). Virus titers were determined as described by Eichwald et al. (17) and expressed as 326 
“viroplasm forming units” (VFU/ml). Purified DLPs were obtained by CsCl gradient purification 327 
from infected MA104 cells, essentially as described by Patton et al., 2000 (40). 328 
For experiments of VLS production and VP6 overexpression in uninfected cells, MA104 329 
cells were infected, respectively, with a T7 RNA polymerase recombinant vaccinia virus 330 
(strain vvTF7.3) (41), and vvT7/LacOI/VP6 virus (vvVP6), an IPTG-inducible recombinant 331 
vaccinia virus driving expression of both the T7 RNA polymerase and VP6 under induction 332 
with 1mM IPTG. For generation of vvVP6, BSC-40 cells were infected with recombinant 333 
vaccinia virus vvT7/LacOI (42) and transfected with pVOTE.1-VP6. Selection and 334 
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 15 
amplification were carried out as described by Earl and Moss (43). The plasmid pVOTE.1 and 335 
vvT7/LacOI were kindly provided by B. Moss.  336 
For the heterologous production of VP6 protein, the recombinant baculovirus BacVP6C 337 
(44) was kindly provided by D. Poncet. 338 
Chemicals. Cells were treated with ML (from 5 to 20 μM, Merck Millipore) following the kinetic 339 
indicated in the Results section. Actinomycin D (0.1 μg/ml, Sigma), okadaic acid (0.5 μM, 340 
Sigma), and cycloheximide (0.1 μg/ml, Sigma) were added to cells from 3 to 8 hours post-341 
infection (hpi). Purified DLPs were treated with ML (from 2.5 to 200 μM, as indicated in the 342 
Results section) or with 200 μM of irrelevant compound (ID #7749832, ChemBridge Corp). 343 
Plasmid constructions. The plasmids pcDNA3-NSP5, -NSP2, -VP6 and -VP2 used to 344 
overexpress RV proteins in uninfected cells were already described previously (13, 35, 45). 345 
The plasmid pVOTE.1-VP6 was obtained by PCR amplification of VP6 mouse EC strain, 346 
using specific primers (5’-ATGCCCATGGATGTGCTGTACTCCATC-3’ and 5’-347 
GATCGGATCCTCACTT TACCAGCATGCTTCT-3’) to incorporate NcoI and BamHI 348 
restriction sites at the 5’ and 3’ ends, respectively. The amplified fragment was ligated 349 
between NcoI and BamHI restriction sites in pVOTE.1 (42). All primer sequences used in this 350 
study for PCR and sequencing are available upon request to the authors. 351 
Infections and transient transfections. Infection experiments with RV were carried out at 352 
an MOI of 25 VFU/cell (17). For overexpression of RV proteins in uninfected cells, confluent 353 
monolayers of MA104 cells in 12-well plates were infected with vvTF7.3 at an MOI of 10 354 
pfu/cell (41, 46). At 1 hpi, cells were transfected with a total of 2 µg of DNA plasmid using 355 
Lipofectamine 3000 (ThermoFisher Scientific) according to the manufacturer’s instructions. At 356 
16 hpi, cells were washed once to remove serum and then treated with 10 μM ML in serum-357 
free DMEM medium for 5 hours. Cells were then collected for immunofluorescence or 358 
 o
n
 January 29, 2020 at G
lasgow University Library
http://jvi.asm.org/
D
ow
nloaded from
 
 16 
Western blot analyses. For VP6 overexpression, confluent monolayers of MA104 cells in 12-359 
well plates were infected with vvVP6 (MOI; 10 pfu/cell). At 1 hpi, both 1mM IPTG and 10 μM 360 
ML were added, and 7 h later cells were collected for immunofluorescence or Western blot 361 
analyses. 362 
For experiments with siRNAs against VP6 (siVP6-OSU: 363 
UGGAACCAUCAUAGCUAGAAA; siVP6-SA11: UGGAACUAUCGUAGCUAGAAA), 5x104 364 
MA104 cells per well were seeded into 12-well plates and the next day transfected with 0.1 365 
nmol of annealed duplex siRNA (Sigma) using 5 μl of RNAiMAX Lipofectamine 2000 366 
(ThermoFisher Scientific) according to the manufacturer’s instructions. Control siRNAs were 367 
siNSP5-SA11 and siNSP5-OSU here referred as siNT and described by Campagna et al., 368 
2005 (7). At 48 hpt cells were infected at the same MOI and collected at 6 hpi (for viroplasm 369 
counting by immunofluorescence or Western blot analyses).  370 
Cellular extracts (about 3 x 105 cells) were prepared with 50 μl of reducing SDS buffer 371 
(125 mM Tris-HCl pH 6.8, 6% SDS, 40% glycerol, 5% β-mercaptoethanol, 0.04% 372 
bromophenol blue) and subsequently sonicated with a VialTweeter (Hielscher Ultrasonics 373 
GmbH) for 1 min (10 W, pulse 0.5 sec) to disrupt DNA. Typically, 10 μl of cellular extracts 374 
were loaded onto an SDS-polyacrylamide gel for Western blot analyses. For VP6 trimer 375 
analyses, cellular extracts were prepared in TNN lysis buffer (100 mM Tris-HCl, pH 8, 250 376 
mM NaCl, 0.5% NP-40 and 30 mM N-ethylmaleimide) and centrifuged at 5,000 x g for 5 min 377 
at 4˚C. For immunoprecipitation assays, cellular extracts were prepared in 378 
radioimmunoprecipitation assay (RIPA) buffer (10 mM Tris-HCl, 1% Triton X-100, 0.5% 379 
sodium deoxycholate, 1 mM EDTA, 150 mM NaCl [pH 7.4]), incubated on ice for 15 min, and 380 
then centrifuged at 13,000 x g for 5 min at 4˚C. 381 
 o
n
 January 29, 2020 at G
lasgow University Library
http://jvi.asm.org/
D
ow
nloaded from
 
 17 
Immunoprecipitation and protein analysis. For immunoprecipitation assays, usually 4/5 of 382 
the total extract, i.e. approximately 80 μl, were immunoprecipitated for 2h at 4°C after addition 383 
of 100 μl of an undiluted mouse anti-VP6 (clone RV138) monoclonal antibody supernatant 384 
(47) (kindly provided by D. Agnello and P. Pothier), 1 μl of a Protease Inhibitor Cocktail 385 
(Sigma), and 50 μl of 50% immobilised rProtein A beads (Repligen Bioprocessing) in RIPA 386 
buffer. Beads were washed four times with RIPA buffer, followed by one wash with PBS and 387 
resuspended in 20 μl of loading buffer. Proteins were separated by SDS-polyacrylamide gel 388 
and transferred to polyvinylidene difluoride membranes (Millipore, IPVH00010) (48). For 389 
protein analysis of either cellular extracts or immunoprecipitated proteins, membranes were 390 
incubated with the following primary antibodies: anti-NSP5 (1:10,000) (46), anti-VP2 (1:5,000) 391 
(35), anti-RV (1:2,500) (17), anti-VP1 (1:5,000) (35) guinea pig sera, anti-NSP3 rabbit serum 392 
(1:1,500) (kindly provided by S. López), anti-NSP4 rabbit serum (1:1,1000) (kindly provided 393 
by D. Luque), anti-VP5 clone 2G4 mouse monoclonal antibody (1:2,000) (kindly provided by 394 
H. Greenberg), anti-alpha-tubulin mouse monoclonal antibody (1:3,000, Calbiochem), anti-395 
actin rabbit polyclonal antibody (1:1,000, Sigma). The membranes were then incubated with 396 
the corresponding HRP-conjugated goat anti-guinea pig (1:10,000, Jackson 397 
ImmunoResearch), goat anti-mouse (1:5,000, Jackson ImmunoResearch), goat anti-rabbit 398 
(1:5,000, Thermo Scientific Pierce) secondary antibodies. Signals were detected by using the 399 
enhanced chemiluminescence system (Pierce ECL Western Blotting Substrate, Thermo 400 
Scientific). 401 
Immunofluorescence microscopy. Immunofluorescence experiments were performed as 402 
described previously (49) using the following antibody dilutions: anti-NSP5 guinea pig serum 403 
1:1,000; anti-VP6 mouse monoclonal antibody (clone 4B2D2) 1:1,000 (kindly provided by J. L. 404 
Zambrano and F. Liprandi); Alexa Fluor® 488-conjugated anti-mouse (1:500, Life 405 
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Technologies) and Alexa Fluor® 546-conjugated anti-rabbit (1:500, Life Technologies) 406 
secondary antibodies. Newly synthesized RNAs were labeled using 2 mM ethylene uridine 407 
(EU) ribonucleotide homolog containing an alkyne reactive group, and the modified 408 
incorporated nucleotide was revealed with an azide-containing fluorophore (Alexa-488, 409 
green), as described for Click-iT® RNA Alexa Fluor® 488 Imaging Kit (Thermo Fisher 410 
Scientific). Cell nuclei were stained with 2 μg/ml Hoechst 33342 (Molecular Probes, Life 411 
Technologies). Samples were analyzed by confocal microscopy (Zeiss LSM510 equipped 412 
with a 100x NA 1.3 objective), and images were processed using LSM Image Examiner 4.0 413 
Software. 414 
Analysis of RV genome segments. Total RNA was purified from MA104 cells infected with 415 
OSU (MOI; 25 VFU/cell) after treatment with 10 μM ML or a control vehicle (dimethyl 416 
sulfoxide, DMSO) from 1 to 6 hpi. Crude viral preparations were digested with 10 μg/ml of 417 
proteinase K (Thermo Fisher Scientific) in the presence of 5 mM EDTA and 0.5% SDS, for 30 418 
min at 60°C. RNA was then purified by phenol-chloroform extraction and precipitation with 5M 419 
ammonium acetate and quantified using the NanoDrop 1000 Spectrophotometer (Thermo 420 
Fisher Scientific). 3.5 μg of total RNA were separated by Tris-glycine nondenaturing 421 
polyacrylamide (4% stacking gel, 10% resolving gel) and transferred to a charged nylon 422 
membrane (GeneScreen Plus Hybridization Transfer Membrane, Perkin Elmer). The 423 
membrane was blocked with 5% milk and 50 μg/ml DNA fish sperm (Affymetrix) in PBS and 424 
was incubated overnight with the mouse anti-dsRNA (clone J2) monoclonal antibody (1:1,000; 425 
English and Scientific Consulting Bt., Hungary) (50), followed by reaction with HRP-426 
conjugated goat anti-mouse antibody (1:5,000, Jackson ImmunoResearch). 427 
Cell viability assay. 2x105 MA104 cells were seeded in 12-well plates. After infection and 428 
drug treatment for the indicated time points, supernatants were removed and stored and cells 429 
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were trypsinized (0.5% trypsin-EDTA, Gibco, ThermoFisher Scientific) and then mixed with 430 
supernatants in order not to lose suffering cells possibly detached. After centrifugation at 900 431 
x g for 2 min at room temperature (RT), pellets were resuspended in 200 µl of 0.5 ng/µl 432 
propidium iodide in PBS and incubated in the dark for 15 min at RT. Samples were diluted to 433 
1 ml with PBS, filtered using a cell strained snap-cap tube (BD Falcon™) and immediately 434 
acquired in a Gallios™ Flow Cytometer (Beckman Coulter, Inc.). For this purpose, 10,000 435 
events were acquired, exciting at 488 nm with an argon laser and a filter band of 675/20 BP. 436 
Data were analyzed gating on live cells using a Kaluza® Flow Analysis Software. The 437 
statistical analysis and plot were performed using Microsoft® Excel® for MAC 2011 Version 438 
14.7.0. 439 
Determination of progeny virus yield. 2x105 MA104 cells seeded in 12-well plates were 440 
RV-infected with an MOI of 25 VFU/cell. Virus adsorption was performed for 1 h at 4˚C, 441 
followed by incubation at 37˚C. At 2 hpi, cells were washed twice with PBS and 10µM ML or 442 
vehicle (2% DMSO) diluted in 500µl DMEM was added. At the indicated time points, plates 443 
were frozen at -80˚C. Cells were then treated with three freeze-thaw cycles, harvested and 444 
centrifuged at 17,000 x g for 5 min at 4˚C. The supernatant was recovered and activated with 445 
80µg/ml of trypsin for 30 min at 37˚C. Serial dilutions were prepared and used to determine 446 
the viral titers as described by Eichwald et al., 2012 (17). 447 
In vitro transcription assays with purified DLPs. 1 μg of purified DLPs were incubated for 448 
4 h at 42°C in a total volume of 100 μl of 1X T7 transcription buffer from Promega, 2mM of 449 
each NTP, 0.5 mM SAM, 0.1 mM MnCl2, 1mM DTT, 0.4 U RNAsin® (Promega). RNA was 450 
isolated using the GeneJET RNA Cleanup and concentration Micro kit (Thermo Fisher 451 
Scientific) and quantified using the Qubit RNA Assay Kits associated to a Qubit 2.0 452 
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Fluorometer (Thermo Fisher Scientific). The statistical analyses were performed using 453 
Student’s t-Test by comparing vehicle and ML-treated particles of each viral strain. 454 
Production of recombinant Baculovirus VP6. A Sf9 suspension culture (1 x 106 cells/ml) 455 
was infected with recombinant baculovirus BacVP6C (27). At 3 days post-infection, cells were 456 
harvested by centrifugation at 180 x g for 20 min at 4°C. The cellular pellet was resuspended 457 
in 10 ml of 20 mM MOPS buffer (pH 6.8) followed by dilution in one volume of 458 
trichlorofluoromethane (Sigma). The sample was vortexed for 1 min and centrifuged at 4,500 459 
x g for 5 min at 4°C. The aqueous phase was transferred to a new tube and this step 460 
repeated twice. The sample was then ultracentrifuged at 100,000 x g with a Beckman SW70.2 461 
rotor for 3 h at 4˚C. The pellet was resuspended in 3 ml of 50 mM Tris-HCl, pH 8.0, 150 mM 462 
CaCl2, 200 mM NaCl to promote formation of VP6 isolated trimers. Trimeric VP6 was further 463 
purified by size exclusion chromatography (Superdex200 16/60 equipped on an AKTA 464 
system) and stored at 4 °C. 465 
Transmission electron microscopy. For detection of viroplasms, MA104 cells were seeded 466 
at 1x105 cells in a 2 cm2 well onto sapphire discs and infected with OSU [MOI: 100 VFU/cell] 467 
(17). At 1 hpi, 20 µM ML was added. At 6 hpi, cells were fixed with 2.5% glutaraldehyde in 468 
100 mM Na/K-phosphate buffer, pH 7.4 for 1 h at 4˚C and kept in 100 mM Na/K-phosphate 469 
buffer overnight at 4˚C. Afterwards, samples were post-fixed in 1% osmium tetroxide in 100 470 
mM Na/K-phosphate buffer for 1 h at 4˚C, dehydrated in a graded ethanol series starting at 471 
70% followed by two changes in acetone and embedded in epon. Ultrathin sections (60-80 472 
nm) were cut, stained with uranyl acetate and lead citrate. For EM analyses of purified DLPs 473 
incubated with ML for 4 h at 42˚C (in the same buffer used in in vitro transcription assays), 474 
DLPs were adsorbed for 10 min on glow-discharged carbon-coated Parlodion films mounted 475 
on 300 mesh per inch copper grids (EMS). Samples were washed once with distilled water 476 
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and stained with saturated uranyl acetate (Fluka) for 1 min at RT. Samples were analyzed in 477 
a transmission electron microscope (CM12, Philips, Eindhoven, The Netherlands) equipped 478 
with a CCD camera (Ultrascan 1000, Gatan, Pleasanton, CA, USA) at an acceleration of 100 479 
kV. For negative staining EM experiments of purified VP6, aliquots of trimeric VP6 (0.5 mg/ml) 480 
were dialyzed overnight at 4˚C against either 50 mM MOPS, pH 6.0, 50 mM NaCl or 50 mM 481 
sodium acetate, pH 4.0 to reconstitute VP6 nanotubes and spheres, respectively. After 482 
dialysis, VP6 samples were recovered and incubated in the presence or absence of 25 µM 483 
ML for 4 h at 37˚C (1% DMSO in both conditions). Prior to sample application, the 400-mesh 484 
copper carbon-coated grids (Agar Scientific) were glow-discharged for 30 sec at 30 mA using 485 
a GloQube system (Quorum Technologies). A 4-μl drop of the incubated VP6 samples at a 486 
final concentration of 0.25 mg/ml was applied to the glow-discharged grid and incubated for 1 487 
min. The grid was immediately stained by gentle stirring for 1 min using 2% (w/v) uranyl 488 
acetate solution. After staining, the grid was blotted dry and imaged on a Tecnai G2 T20 LaB6 489 
transmission electron microscope (FEI) operating at 200 KeV. Images were manually 490 
acquired on an Eagle 2K CCD camera (FEI) at a nominal magnification of 50,000× 491 
(corresponding to a pixel size of 4.55 Å at the specimen level) and defocus values in the 492 
range of 1.5 μm to 2.5 μm. 493 
Microscale thermophoresis. Thermophoresis was used to determine the binding affinities 494 
between recombinant purified VP6 and ML. Experiments were performed in standard 495 
capillaries using a Monolith™ NT.115 instrument (NanoTemper Technologies). Either 496 
cysteines or lysines of VP6 were labeled with maleimide or NHS dye, respectively, following 497 
the manufacturer protocol. Labeled VP6 (100 nM) was incubated at 37 °C for 4 h with 498 
increasing concentration of ML (0 to 106 nM) in MST buffer (50 mM Tris-HCl, pH 7.4, 150 mM 499 
NaCl, 10 mM MgCl2, 0.05% Tween-20) supplemented with 10% DMSO. Thereafter, 500 
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measurements were performed at 24 °C using 20% LED power and 20% MST power. The 501 
addition of ML causes quenching of the fluorescent protein due to specific binding, as 502 
assessed by the SD-test; therefore, initial fluorescence was used to calculate the affinity. Data 503 
were analyzed according to the Hill model (cooperative binding) using the NanoTemper 504 
software. Reported affinity value is the average of three independent experiments. 505 
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 671 
FiGURE LEGENDS 672 
Fig. 1. ML effect on RV replication. (A-E) Western blot and confocal immunofluorescence 673 
analysis with the indicated antibodies of RV-infected cells (MOI, 25 VFU/cell) treated with ML 674 
at 10 μM, unless otherwise indicated, or DMSO (D) for the indicated time windows. Scale 675 
bars, 10 μm. (F) Time course of viral progeny yield of OSU-infected (MOI, 25 VFU/cell) 676 
MA104 cells treated with 10 μM ML, added at 2 hpi. Data are presented as average ± 677 
standard deviation of three independent experiments. t-Test, (***) p<0.001. (G) Genome 678 
segments analysis of blotted total RNA extracted from non-infected (NI) and OSU-infected 679 
MA104 cells (25 VFU/cell) treated with ML (10 μM) or DMSO from 1 to 8 hpi and revealed 680 
with an anti-dsRNA antibody. (H) Viability of non-infected or OSU-infected (MOI, 25 VFU/cell) 681 
MA104 cells determined by cytofluorometry of propidium iodide stained cells following 682 
treatment at 2 hpi with or without 10 µM ML for up to 12 hpi. Data are presented as average ± 683 
standard deviation of three independent experiments. T-test, (*)p<0.05; (**) p<0.01 and (***) 684 
p<0.001. 685 
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Fig. 2. Electron microscopy of RV-infected cells treated with ML. High-definition electron 686 
microscopy of non-infected (NI) and RV-infected (OSU; MOI, 100 VFU/ml) MA104 cells 687 
untreated (DMSO) or treated with ML (20 µM) from 1 hpi. At 6 hpi, cells were fixed with 688 
glutaraldehyde and processed for transmission electron microscopy. V, viroplasms; Nu, 689 
nucleus, ER, endoplasmic reticulum; Gg, Golgi complex; Vc, vacuoles; Ph, phagosomes; CM, 690 
cell membrane; thin white arrows indicate the endoplasmic reticulum membrane surrounding 691 
viroplasms; solid white arrowheads indicate viral particles. The corresponding scale bars are 692 
shown in each image. 693 
Fig. 3. NSP5 dephosphorylation caused by ML-mediated viroplasm disruption. Western 694 
blot and confocal immunofluorescence analysis with the indicated antibodies of OSU-infected 695 
MA104 cells (25 VFU/cell) treated with 10 μM ML and/or 0.5 μM okadaic acid (OA) or DMSO 696 
for the indicated time windows. Scale bars, 5 μm. 697 
Fig. 4. ML antiviral activity is independent of cellular transcription and protein 698 
synthesis. (A) Western blot and confocal immunofluorescence analysis with the indicated 699 
antibodies of OSU-infected MA104 cells (25 VFU/cell) fed with ethynyl uridine (EU) and 700 
treated with 10 μM ML and/or 10 μg/ml actinomycin D or DMSO for the indicated time 701 
windows. EU-labeled, newly synthesized RNAs were visualized by reaction with an Alexa-488 702 
conjugated azide (green). Scale bars, 5 μm. (B) Western blot and confocal 703 
immunofluorescence with the indicated antibodies of OSU-infected (MOI, 25 VFU/cell) MA104 704 
cells treated with 10 μM ML and/or 10 μg/ml cycloheximide (CHX) or DMSO for the indicated 705 
time windows. Scale bars, 10 μm. 706 
Fig. 5. ML-mediated impairment of DLP stability. (A) Transcriptional activity of purified 707 
DLPs. The plot shows the dose-dependent decrease of transcripts produced by SA11 or OSU 708 
DLPs incubated in the presence of the indicated concentrations of ML. The small molecule ID 709 
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#7749832 (ChemBridge Corp.) at 200 μM was used as an irrelevant compound (irr.). The 710 
data represent the mean ± standard deviation of at least three independent experiments. t-711 
Test, (**)p<0.01, (***)p<0.001 and ns, p>0.01. (B-C) DLPs morphology analyzed by electron 712 
microscopy. Purified DLPs were incubated for 4 h with the indicated concentrations of ML or 713 
DMSO. Open white arrows indicate damaged DLPs with an irregular shape and partially 714 
open. Quantification of damaged DLPs is shown in C. The data in graph C are presented as 715 
average ± SEM; t-test (***) p<0.001; n>100. 716 
Fig. 6. Effect of ML on RV VP6. (A) VP6-VP2 interaction. Western blot analysis with anti-717 
VP2 and anti-VP6 antibodies of immunoprecipitates (IP) obtained with anti-VP6 mAb RV138 718 
from extracts of MA104 cells transfected with VP6 and VP2 and treated for 5 h with 10 μM ML 719 
or DMSO. The inhibitor (200 μM) was maintained during cell lysis and incubation with the 720 
precipitating antibody. (B) VP6 trimer stability. Left panel: Western blot analysis with anti-VP6 721 
antibody of non-boiled extracts from MA104 cells infected with a recombinant vaccinia virus 722 
expressing VP6 (vvVP6) and treated with 10 μM ML or DMSO from 1 to 7 hpi. Right panel: 723 
Western blot analysis of non-boiled extracts from cells infected with OSU (MOI, 25 VFU/cell) 724 
treated with 10 μM ML or DMSO from 1 to 5 hpi. (C) Confocal immunofluorescence analysis 725 
with the anti-VP6 mAb 4B2D2 of MA104 cells overexpressing VP6 (infected with vvVP6) and 726 
treated with 10 μM ML or DMSO from 1 to 7 hpi. The white arrow indicates a VP6 higher 727 
order structure observed in the absence of other RV proteins. Scale bars, 5 μm. (D) 728 
Representative images of VP6 tubes and spheres visualized by negative staining electron 729 
microscopy after treatment with 25 µM ML for 4 h at 37˚C. Scale bar, 100 nm. (E) Interaction 730 
of VP6 with ML evaluated by nanoscale thermophoresis. The fraction of Cys- or Lys-labeled 731 
VP6 bound to ML was plotted against increasing concentrations of the inhibitor. Data were 732 
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fitted with two state equations and an EC50 of 294  62 µM calculated as the average of three 733 
independent measurements.  734 
Fig. 7. ML effect on VLS. Confocal immunofluorescence of VLS (A, C) and Western blot 735 
analysis (B) with the indicated antibodies of MA104 cells transfected with NSP5, NSP2, VP2 736 
and VP6, as indicated. In (A) NSP5 is shown in green and NSP2 or VP2 in red. In (C) NSP5 737 
is shown in red, and VP6 in green. Cells were treated for 5 h with 10 μM ML or DMSO at 18 h 738 
post-transfection.  739 
Fig. 8. VP6 in RV-infected cells. Confocal immunofluorescence of MA104 cells infected with 740 
either OSU or SA11 (MOI, 25 VFU/cell) and: A) transfected with siRNAs specific for SA11 741 
VP6 or OSU VP6, or with a non-targeting siRNA (siNT); B) treated with 10 μM ML or DMSO. 742 
At the times points post-infection indicated viroplasms were visualized with anti-NSP5 743 
antibody (red) and VP6 with mAb 4B2D2 (green). Scale bars, 5 μm. 744 
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